دورية أكاديمية
Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects.
| العنوان: | Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects. |
|---|---|
| المؤلفون: | Hegde MM; Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India., Sandbhor P; Department of Biosciences and Bioengineering, Indian Institute of Technology, Mumbai, India., J A; Advance Centre for Treatment Research and Education in Cancer, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India., Gota V; Advance Centre for Treatment Research and Education in Cancer, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India., Goda JS; Advance Centre for Treatment Research and Education in Cancer, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India. |
| المصدر: | Frontiers in oncology [Front Oncol] 2023 Jul 06; Vol. 13, pp. 1168454. Date of Electronic Publication: 2023 Jul 06 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Tumors of the Central nervous System (CNS) are a spectrum of neoplasms that range from benign lesions to highly malignant and aggressive lesions. Despite aggressive multimodal treatment approaches, the morbidity and mortality are high with dismal survival outcomes in these malignant tumors. Moreover, the non-specificity of conventional treatments substantiates the rationale for precise therapeutic strategies that selectively target infiltrating tumor cells within the brain, and minimize systemic and collateral damage. With the recent advancement of nanoplatforms for biomaterials applications, lipid-based nanoparticulate systems present an attractive and breakthrough impact on CNS tumor management. Lipid nanoparticles centered immunotherapeutic agents treating malignant CNS tumors could convene the clear need for precise treatment strategies. Immunotherapeutic agents can selectively induce specific immune responses by active or innate immune responses at the local site within the brain. In this review, we discuss the therapeutic applications of lipid-based nanoplatforms for CNS tumors with an emphasis on revolutionary approaches in brain targeting, imaging, and drug and gene delivery with immunotherapy. Lipid-based nanoparticle platforms represent one of the most promising colloidal carriers for chemotherapeutic, and immunotherapeutic drugs. Their current application in oncology especially in brain tumors has brought about a paradigm shift in cancer treatment by improving the antitumor activity of several agents that could be used to selectively target brain tumors. Subsequently, the lab-to-clinic transformation and challenges towards translational feasibility of lipid-based nanoplatforms for drug and gene/immunotherapy delivery in the context of CNS tumor management is addressed. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Hegde, Sandbhor, J., Gota and Goda.) |
| References: | Nat Nanotechnol. 2013 Feb;8(2):137-43. (PMID: 23334168) Ther Deliv. 2018 Mar 1;9(4):269-285. (PMID: 29495928) Lancet Oncol. 2008 May;9(5):453-61. (PMID: 18452856) J Control Release. 2017 Oct 28;264:306-332. (PMID: 28844756) Br J Pharmacol. 2016 Feb;173(4):649-65. (PMID: 25800044) JAMA Oncol. 2017 Aug 01;3(8):1094-1101. (PMID: 28426845) Curr Opin Oncol. 2016 Jul;28(4):306-13. (PMID: 27136134) Cancer. 2004 Mar 15;100(6):1199-207. (PMID: 15022287) Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. (PMID: 28233053) Biomed Pharmacother. 2023 Jan;157:113998. (PMID: 36399829) N Engl J Med. 2016 Dec 29;375(26):2561-9. (PMID: 28029927) Nano Lett. 2022 Jan 12;22(1):533-542. (PMID: 34669421) Oncotarget. 2015 Oct 6;6(30):30194-211. (PMID: 26327203) Nat Rev Drug Discov. 2004 Jun;3(6):499-508. (PMID: 15173839) Acad Med. 2012 Mar;87(3):266-70. (PMID: 22373616) Int J Nanomedicine. 2013;8:689-702. (PMID: 23467447) J Neuroimmunol. 1989 Dec;25(2-3):185-93. (PMID: 2584396) Nat Rev Immunol. 2018 Mar;18(3):183-194. (PMID: 29279613) Front Pharmacol. 2015 Dec 01;6:286. (PMID: 26648870) Cancer Res. 2003 Dec 15;63(24):8996-9006. (PMID: 14695218) PLoS One. 2014 Jan 08;9(1):e82331. (PMID: 24416140) J Immunol. 2018 Jan 15;200(2):422-431. (PMID: 29311384) Neuroreport. 1997 May 27;8(8):1995-8. (PMID: 9223091) Adv Healthc Mater. 2021 Mar;10(5):e2100243. (PMID: 33655680) Front Immunol. 2021 Jul 19;12:701006. (PMID: 34349762) Curr Gene Ther. 2021;21(5):452-463. (PMID: 33390137) Stroke. 2016 Feb;47(2):498-504. (PMID: 26732561) J Pharm Sci. 2013 Nov;102(11):3867-82. (PMID: 24037829) Oncoimmunology. 2016 Nov 18;6(1):e1256527. (PMID: 28197373) Immunol Today. 1992 Dec;13(12):507-12. (PMID: 1463583) Pharm Res. 2002 Oct;19(10):1430-8. (PMID: 12425459) Cell. 1995 Apr 21;81(2):179-83. (PMID: 7736570) Ann Neurol. 2003 Oct;54(4):479-87. (PMID: 14520660) Curr Top Microbiol Immunol. 2002;265:1-22. (PMID: 12014185) Oncotarget. 2016 Jun 7;7(23):34158-71. (PMID: 27120809) Front Pharmacol. 2017 Mar 31;8:166. (PMID: 28408882) Mol Ther. 2017 Dec 6;25(12):2607-2619. (PMID: 28919377) Micron. 2011 Dec;42(8):793-800. (PMID: 21616673) Nanomedicine (Lond). 2017 Oct;12(20):2533-2554. (PMID: 28952878) Acc Chem Res. 2022 Jan 4;55(1):2-12. (PMID: 34850635) Ann N Y Acad Sci. 2014 Apr;1313:35-56. (PMID: 24673240) J Neurooncol. 2014 May;118(1):73-82. (PMID: 24664370) Int J Mol Sci. 2014 Feb 27;15(3):3612-23. (PMID: 24583850) J Pathol. 1989 Oct;159(2):143-9. (PMID: 2530324) Clin Transl Oncol. 2019 Nov;21(11):1441-1449. (PMID: 31055713) Diagnostics (Basel). 2022 Jan 12;12(1):. (PMID: 35054340) J Cell Mol Med. 2013 Jan;17(1):30-54. (PMID: 23301832) Mol Pharm. 2014 Jun 2;11(6):1823-34. (PMID: 24779677) Brain Res Brain Res Rev. 1995 Mar;20(3):269-87. (PMID: 7550361) Immunol Rev. 2014 Jan;257(1):56-71. (PMID: 24329789) Mol Ther. 2017 Sep 6;25(9):2189-2201. (PMID: 28676342) Nat Commun. 2019 Jan 25;10(1):448. (PMID: 30683885) Ann Neurol. 2006 Jul;60(1):3-11. (PMID: 16802285) J Immunol Res. 2020 Jan 21;2020:8459496. (PMID: 32411806) Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. (PMID: 33123732) J Control Release. 2014 Jan 10;173:110-8. (PMID: 24120854) Curr Pharm Des. 2010 Jun;16(16):1882-92. (PMID: 20222866) Cell Rep. 2016 Apr 12;15(2):274-87. (PMID: 27050509) Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441) Cancer. 2002 Jun 15;94(12):3210-8. (PMID: 12115353) J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72. (PMID: 22929442) Nat Rev Cancer. 2020 Jan;20(1):12-25. (PMID: 31806885) Trends Immunol. 2012 Dec;33(12):579-89. (PMID: 22926201) Integr Biol (Camb). 2013 Jan;5(1):96-107. (PMID: 22869005) Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14. (PMID: 26516226) Clin Cancer Res. 2013 Jun 15;19(12):3165-75. (PMID: 23613317) Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305. (PMID: 16857805) Mol Pharm. 2020 Jun 1;17(6):1996-2005. (PMID: 32365295) Biomater Sci. 2016 Feb;4(2):219-29. (PMID: 26646694) Oncotarget. 2014 Dec 30;5(24):12472-508. (PMID: 25537519) Theranostics. 2018 Feb 5;8(6):1481-1493. (PMID: 29556336) Lab Invest. 2012 Jan;92(1):151-62. (PMID: 21894147) J Neurooncol. 2021 Jan;151(1):3-12. (PMID: 32542437) Pharmaceutics. 2020 Aug 27;12(9):. (PMID: 32867162) Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571) Oncotarget. 2015 Oct 20;6(32):33077-90. (PMID: 26427514) Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9. (PMID: 17482475) Cancer Lett. 2016 Oct 1;380(2):545-551. (PMID: 25527451) J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9. (PMID: 11895036) Biomaterials. 2012 Nov;33(32):8167-76. (PMID: 22889488) Immunol Today. 1994 Dec;15(12):566-71. (PMID: 7848517) Int J Mol Sci. 2019 Jul 26;20(15):. (PMID: 31357555) Surg Neurol Int. 2016 May 06;7(Suppl 11):S295-9. (PMID: 27217968) Ital J Pediatr. 2018 Nov 16;44(Suppl 2):131. (PMID: 30442184) Nat Med. 2013 Oct;19(10):1264-72. (PMID: 24056773) Int J Nanomedicine. 2020 Apr 23;15:2809-2828. (PMID: 32368056) Glia. 2005 Sep;51(4):279-85. (PMID: 15818597) Clin Cancer Res. 2020 Aug 15;26(16):4369-4380. (PMID: 32439701) J Nanobiotechnology. 2022 Jan 21;20(1):45. (PMID: 35062958) Immunol Rev. 2019 Jul;290(1):60-84. (PMID: 31355493) Int J Oncol. 2007 Feb;30(2):499-507. (PMID: 17203233) Cancer Res. 2018 Jul 1;78(13):3718-3730. (PMID: 29760047) Front Mol Neurosci. 2021 Oct 05;14:722396. (PMID: 34675774) Cancer Res. 2006 Aug 15;66(16):7843-8. (PMID: 16912155) Nat Rev Cancer. 2020 Jan;20(1):26-41. (PMID: 31601988) J Neuroimmunol. 1999 Nov 15;101(2):111-27. (PMID: 10580795) Trends Immunol. 2002 Nov;23(11):549-55. (PMID: 12401408) Nat Nanotechnol. 2012 Dec;7(12):779-86. (PMID: 23212421) JCI Insight. 2016;1(2):. (PMID: 26973881) Handb Exp Pharmacol. 2018;249:109-128. (PMID: 28315073) Nanomedicine. 2016 May;12(4):893-900. (PMID: 26772431) Nanomedicine. 2009 Sep;5(3):251-73. (PMID: 19540359) J Neurooncol. 2006 Jan;76(1):13-21. (PMID: 16136272) Mol Cell Biol. 1991 May;11(5):2656-64. (PMID: 2017171) Nanoscale. 2017 Aug 3;9(30):10919-10932. (PMID: 28731079) ESMO Open. 2022 Feb;7(1):100365. (PMID: 34998092) J Vis Exp. 2016 Jul 23;(113):. (PMID: 27501362) Gene Ther. 1997 Mar;4(3):210-8. (PMID: 9135734) FASEB J. 1991 Feb;5(2):171-7. (PMID: 1825981) ACS Nano. 2020 Jul 28;14(7):7832-7846. (PMID: 32413260) Clin Cancer Res. 2012 Nov 15;18(22):6110-21. (PMID: 22932670) Vaccines (Basel). 2015 Sep 10;3(3):703-29. (PMID: 26378585) Stem Cells. 2010 Jun;28(6):1019-29. (PMID: 20506127) Glia. 2016 Aug;64(8):1416-36. (PMID: 27312099) J Immunol. 2005 May 1;174(9):5215-23. (PMID: 15843517) Front Oncol. 2021 Jan 29;10:603495. (PMID: 33585220) Annu Rev Neurosci. 2018 Jul 8;41:207-232. (PMID: 29641939) J Formos Med Assoc. 2020 Mar;119(3):728-734. (PMID: 31515159) J Immunother Cancer. 2021 May;9(5):. (PMID: 34035114) Biomaterials. 2008 Aug-Sep;29(24-25):3477-96. (PMID: 18499247) Eur J Immunol. 2013 May;43(5):1173-84. (PMID: 23529826) Int J Mol Sci. 2018 Feb 13;19(2):. (PMID: 29438283) Nature. 2015 Mar 19;519(7543):300-1. (PMID: 25762139) Target Oncol. 2015 Mar;10(1):1-14. (PMID: 24590691) Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1139-1147. (PMID: 30354685) Cancer Cell. 2004 Oct;6(4):409-21. (PMID: 15488763) Nanomedicine. 2014 Jul;10(5):905-19. (PMID: 24135564) Semin Cell Dev Biol. 2015 Feb;38:2-6. (PMID: 25681530) Int J Nanomedicine. 2016 Oct 18;11:5381-5414. (PMID: 27799765) Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573) Neuro Oncol. 2001 Apr;3(2):82-8. (PMID: 11296484) Biomaterials. 2022 Jun 22;287:121645. (PMID: 35779480) Curr Opin Biomed Eng. 2017 Dec;4:1-12. (PMID: 29333521) J Exp Clin Cancer Res. 2008 Dec 24;27:85. (PMID: 19108713) J Neurol Sci. 1991 Jan;101(1):47-58. (PMID: 2027027) Folia Neuropathol. 1994;32(4):251-2. (PMID: 7889340) Neuro Oncol. 2005 Oct;7(4):452-64. (PMID: 16212810) Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076) ACS Omega. 2020 Jun 01;5(22):12583-12595. (PMID: 32548442) Asian J Pharm Sci. 2019 Sep;14(5):480-496. (PMID: 32104476) Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. (PMID: 21557641) Front Immunol. 2018 Oct 26;9:2486. (PMID: 30416506) Nat Immunol. 2022 Apr;23(4):487-500. (PMID: 35145297) Expert Rev Neurother. 2006 Oct;6(10):1495-509. (PMID: 17078789) Br J Cancer. 2013 Jun 25;108(12):2516-24. (PMID: 23652300) Front Immunol. 2020 Jul 31;11:1549. (PMID: 32903717) Nanoscale Res Lett. 2013 Feb 22;8(1):102. (PMID: 23432972) Int J Nanomedicine. 2015 Sep 10;10(Spec Iss):251-60. (PMID: 26425092) J Exp Med. 1981 Aug 1;154(2):347-61. (PMID: 6943285) Oncotarget. 2015 Jan 1;6(1):171-84. (PMID: 25426558) Drug Deliv. 2016 Oct;23(8):2720-2725. (PMID: 26203691) Cell Immunol. 2017 Dec;322:1-14. (PMID: 29079339) Adv Exp Med Biol. 2020;1202:281-298. (PMID: 32034719) Nat Neurosci. 2016 Jan;19(1):20-7. (PMID: 26713745) Biochem Soc Trans. 2007 Feb;35(Pt 1):68-71. (PMID: 17233603) Mol Ther. 2017 Sep 6;25(9):2214-2224. (PMID: 28602436) Glia. 2018 Jan;66(1):161-174. (PMID: 28948650) AAPS J. 2021 Oct 28;23(6):114. (PMID: 34713363) Int J Mol Sci. 2022 Aug 26;23(17):. (PMID: 36077066) Biomedicines. 2022 Feb 08;10(2):. (PMID: 35203609) Carcinogenesis. 2012 Feb;33(2):312-9. (PMID: 22159219) Springer Semin Immunopathol. 1985;8(1-2):111-27. (PMID: 3890235) Clin Cancer Res. 1999 May;5(5):1107-13. (PMID: 10353745) Biomaterials. 2014 Jul;35(21):5591-604. (PMID: 24726749) Nat Med. 2001 Oct;7(10):1118-22. (PMID: 11590434) Cytokine. 2011 Sep;55(3):387-95. (PMID: 21684758) Mol Ther. 2020 Nov 4;28(11):2320-2339. (PMID: 32979309) ACS Nano. 2019 Feb 26;13(2):1365-1384. (PMID: 30721028) Int J Mol Sci. 2019 Mar 14;20(6):. (PMID: 30875739) Nature. 2016 Jun 01;534(7607):329-31. (PMID: 27281206) Cell Immunol. 2020 Aug;354:104143. (PMID: 32563850) J Neurooncol. 2014 Dec;120(3):489-97. (PMID: 25195130) J Neurocytol. 1989 Jun;18(3):359-68. (PMID: 2746307) Int Rev Cell Mol Biol. 2018;336:175-203. (PMID: 29413890) Clin Cancer Res. 2005 Dec 1;11(23):8304-11. (PMID: 16322289) Drug Discov Ther. 2015 Jun;9(3):205-12. (PMID: 26193943) Hum Immunol. 2015 Aug;76(8):561-4. (PMID: 26116540) Acta Neuropathol. 2000 Feb;99(2):131-7. (PMID: 10672319) Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. (PMID: 23036225) Nat Nanotechnol. 2023 Jan;18(1):86-97. (PMID: 36536041) J Nanobiotechnology. 2021 Dec 23;19(1):446. (PMID: 34949198) Mt Sinai J Med. 2001 May;68(3):160-6. (PMID: 11373688) Genes Dev. 2015 Jun 15;29(12):1203-17. (PMID: 26109046) J Neurooncol. 2010 Aug;99(1):33-40. (PMID: 20157762) Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344) |
| فهرسة مساهمة: | Keywords: CNS tumors; blood-brain barrier; clinical trail; immunotherapy; lipid-based nanoparticles |
| تواريخ الأحداث: | Date Created: 20230724 Latest Revision: 20230725 |
| رمز التحديث: | 20230725 |
| مُعرف محوري في PubMed: | PMC10357293 |
| DOI: | 10.3389/fonc.2023.1168454 |
| PMID: | 37483515 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2023.1168454 |